MetaCap

Harvard Bioscience (HBIO) vs Pacific Biosciences of California (PACB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Harvard Bioscience (HBIO) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 37.5% versus a loss of 26.6%. Over five years, HBIO leads with a -87.4% price change compared with -93.0% for PACB. Pacific Biosciences of California is the larger company by market cap ($508.9 million vs $39.6 million), about 12.9 times the size.

Harvard Bioscience converts more of its revenue into profit, with a net margin of -65.5% versus -341.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HBIO+37.46%PACB-26.58%
+59%+2%-55%
Nov 21, 20251 yearNov 20, 2026
HBIO-88.36%PACB-93.84%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HBIO versus PACB key metrics
MetricHBIOPACB
Share price$8.66$1.63
Market cap$39.60M$508.95M
1-day change-0.23%-7.39%
YTD return+29.25%-12.83%
1-year return+37.46%-26.58%
5-year return-87.45%-93.01%
Forward P/E16.34—
EPS (TTM)$-2.59$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$86.55M$160.00M
Revenue growth (YoY)-8.06%+3.89%
Net income (latest FY)$-56.70M$-546.38M
Gross margin57.67%28.61%
Operating margin-56.13%-346.15%
Net margin-65.51%-341.47%
52-week high$10.20$3.44
52-week low$4.00$1.07
Distance from 52-week high-15.10%-52.62%
Analyst consensusnonebuy
Avg. price target upside-13.39%+68.10%
Average volume21.82K13.23M
Shares outstanding4.57M312.24M
Employees316485
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Pacific Biosciences of California is about 12.9 times larger than Harvard Bioscience by market value ($508.95M vs $39.60M).
  • HBIO has outperformed PACB by 64.0 percentage points over the past year.
  • Harvard Bioscience is more profitable, keeping -65.5 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
  • Pacific Biosciences of California grew revenue faster in its latest fiscal year (+3.89% vs -8.06%).

About Harvard Bioscience

HBIO stock →

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees

About Pacific Biosciences of California

PACB stock →

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees

HBIO vs PACB FAQ

Which is bigger, Harvard Bioscience or Pacific Biosciences of California?

Pacific Biosciences of California (PACB) is larger, with a market capitalization of $508.95M compared with $39.60M for Harvard Bioscience (HBIO).

Which stock has performed better over the past year, HBIO or PACB?

HBIO returned +37.46% over the past 12 months, compared with -26.58% for PACB (price return, excluding dividends). Past performance does not predict future results.

Are Harvard Bioscience and Pacific Biosciences of California in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons